QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.099705v1 317/2/562    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kakui, N. Articles by Kitaguchi, H. Search for Related Content PubMed PubMed Citation Articles by Kakui, N. Articles by Kitaguchi, H.

NEUROPHARMACOLOGY

Pharmacological Characterization and Feeding-Suppressive Property of FMS586 [3-(5,6,7,8-Tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea Hydrochloride], a Novel, Selective, and Orally Active Antagonist for Neuropeptide Y Y5 Receptor

Pharmaceutical Research Department, Meiji Seika Kaisha, Ltd., Kohoku-ku, Yokohama, Japan (N.K., J.T., Y.T., K.As., N.M., T.M., Y.N., F.O.); and Synthetic Organic Chemistry Laboratories, Fuji Photo Film Co., Ltd., Kanagawa, Japan (N.N., M.Sug., M.Suz., K.Ao., H.K.)

We evaluated the pharmacological profiles of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel tetrahydrocarbazole derivative as a neuropeptide Y (NPY) Y5 receptor antagonist. This compound showed a highly selective in vitro affinity for Y5 (IC₅₀ = 4.3 ± 0.4 nM) relative to other NPY receptor subtypes like Y1 or Y2. Its binding to Y5 was found to be fully antagonistic from cyclic AMP accumulation assays in human embryonic kidney 293 cells. Pharmacokinetic analysis revealed sufficient oral availability and brain permeability of this compound accompanied with clear dose relation. We attempted to assess the selectivity of FMS586 and, thereby, to infer the physiological role of Y5 in the following feeding experiments in normal rats. An intracerebroventricular injection of NPY and Y5-selective agonist peptide induced acute and robust feeding responses in satiated rats, and prior administration of FMS586 at the doses from 25 to 100 mg/kg clearly inhibited these responses by approximately 55 and 90%, respectively. This compound also showed dose-dependent but transient suppression in natural feeding models of both overnight fasting-induced hyperphagia and spontaneous daily intake. FMS586 did not modulate food intake induced by the topical injection of norepinephrine, galanin, or -aminobutyric acid receptor agonist muscimol to the paraventricular nucleus. In addition, we confirmed the Y5-specific activity profile of FMS586 by immunohistochemical analysis. Taken together, we propose not only that our compound potentially expresses specific blockade of central Y5 signals but also that Y5 receptor would certainly contribute to physiological regulation of food intake in normal rats, as suggested from its origin.

Address correspondence to: Dr. Nobukazu Kakui, Pharmaceutical Research Department, Meiji Seika Kaisha, Ltd., 760, Moro-oka-cho, Kohoku-ku, Yokohama 222-8567, Japan. E-mail: nobukazu_kakui{at}meiji.co.jp

This article has been cited by other articles:

				M. W. Walker, T. D. Wolinsky, V. Jubian, G. Chandrasena, H. Zhong, X. Huang, S. Miller, L. G. Hegde, D. A. Marsteller, M. R. Marzabadi, et al. J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 900 - 911. [Abstract] [Full Text] [PDF]

				M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF]

				N. Kakui and K. Kitamura Direct Evidence that Stimulation of Neuropeptide Y Y5 Receptor Activates Hypothalamo-Pituitary-Adrenal Axis in Conscious Rats via both Corticotropin-Releasing Factor- and Arginine Vasopressin-Dependent Pathway Endocrinology, June 1, 2007; 148(6): 2854 - 2862. [Abstract] [Full Text] [PDF]